Price (delayed)
$4.395
Market cap
$579.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.81
Enterprise value
$658.08M
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their
There are no recent dividends present for CTIC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.